Efficacy of Semaglutide by Sex in Obesity-Related Heart Failure With Preserved Ejection Fraction: STEP-HFpEF Trials
JACC This Week · American College of Cardiology
August 19, 202410m 16s
Audio is streamed directly from the publisher (traffic.libsyn.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Dr. Valentin Fuster discusses a study on the efficacy of semaglutide for treating obesity-related heart failure with preserved ejection fraction, highlighting that the drug significantly reduced body weight and improved heart failure symptoms in both men and women. Notably, women experienced greater weight loss than men, but this did not translate into better improvement in heart failure-related symptoms, underscoring complex sex-related differences in cardiovascular health.